JP2006514068A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514068A5
JP2006514068A5 JP2004566647A JP2004566647A JP2006514068A5 JP 2006514068 A5 JP2006514068 A5 JP 2006514068A5 JP 2004566647 A JP2004566647 A JP 2004566647A JP 2004566647 A JP2004566647 A JP 2004566647A JP 2006514068 A5 JP2006514068 A5 JP 2006514068A5
Authority
JP
Japan
Prior art keywords
dosage form
prostaglandin
compound
group
solid dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004566647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514068A (ja
Filing date
Publication date
Priority claimed from US10/336,481 external-priority patent/US6841574B2/en
Application filed filed Critical
Publication of JP2006514068A publication Critical patent/JP2006514068A/ja
Publication of JP2006514068A5 publication Critical patent/JP2006514068A5/ja
Pending legal-status Critical Current

Links

JP2004566647A 2003-01-03 2003-12-31 局所安定化プロスタグランジンe化合物剤形 Pending JP2006514068A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/336,481 US6841574B2 (en) 2003-01-03 2003-01-03 Topical stabilized prostaglandin E compound dosage forms
PCT/US2003/041658 WO2004062632A1 (en) 2003-01-03 2003-12-31 Topical stabilized prostaglandin e compound dosage forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011200752A Division JP5395138B2 (ja) 2003-01-03 2011-09-14 局所安定化プロスタグランジンe化合物剤形

Publications (2)

Publication Number Publication Date
JP2006514068A JP2006514068A (ja) 2006-04-27
JP2006514068A5 true JP2006514068A5 (enExample) 2007-02-22

Family

ID=32681022

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004566647A Pending JP2006514068A (ja) 2003-01-03 2003-12-31 局所安定化プロスタグランジンe化合物剤形
JP2011200752A Expired - Fee Related JP5395138B2 (ja) 2003-01-03 2011-09-14 局所安定化プロスタグランジンe化合物剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011200752A Expired - Fee Related JP5395138B2 (ja) 2003-01-03 2011-09-14 局所安定化プロスタグランジンe化合物剤形

Country Status (16)

Country Link
US (1) US6841574B2 (enExample)
EP (1) EP1585483B1 (enExample)
JP (2) JP2006514068A (enExample)
KR (2) KR101174788B1 (enExample)
CN (1) CN100574763C (enExample)
AT (1) ATE468098T1 (enExample)
AU (1) AU2003300113B2 (enExample)
BR (1) BR0317924A (enExample)
CA (1) CA2512015C (enExample)
DE (1) DE60332656D1 (enExample)
DK (1) DK1585483T3 (enExample)
ES (1) ES2343246T3 (enExample)
IL (1) IL169425A (enExample)
PT (1) PT1585483E (enExample)
WO (1) WO2004062632A1 (enExample)
ZA (1) ZA200505321B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
BRPI0408454A (pt) 2003-03-21 2006-04-04 Nexmed Holdings Inc composição tópica, método de tratar a ejaculação precoce, e, uso da composição
WO2005051960A2 (en) * 2003-11-22 2005-06-09 Midwest Research Laboratories, Llc Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060286172A1 (en) * 2005-06-03 2006-12-21 Anu Mahashabde Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
CN101321511A (zh) * 2005-12-06 2008-12-10 莫诺索尔克斯有限公司 递送活性剂的局部用薄膜组合物
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
ES2921527T3 (es) 2009-06-03 2022-08-29 Forsight Vision5 Inc Administración de fármaco en segmento anterior
EP2693877A4 (en) 2011-04-07 2014-11-19 Nexmed Holdings Inc METHOD AND COMPOSITION FOR TREATING RAYNAUD SYNDROME
CN106073986B (zh) 2011-09-14 2019-01-11 弗赛特影像5股份有限公司 治疗患者的眼睛的装置
PT2911623T (pt) 2012-10-26 2019-11-21 Forsight Vision5 Inc Sistema oftálmico para libertação prolongada de fármaco no olho
US8900625B2 (en) 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
WO2019142015A1 (es) * 2018-01-18 2019-07-25 Caicedo Pinto, David Felipe Composicion farmaceutica para la disfuncion erectil de administracion transdermica via uretral en gotas

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883576A (en) * 1971-02-02 1975-05-13 Upjohn Co Prostaglandin E{HD 3 {B analogs
US3826823A (en) * 1972-09-25 1974-07-30 Syntex Inc Stabilized prostaglandin preparations
US3875300A (en) * 1972-12-18 1975-04-01 Ortho Pharma Corp Composition for sustained release of a medicament and method of using same
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US5017382A (en) * 1979-03-21 1991-05-21 National Research Development Corporation Controlled release compositions (II)
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
JPS5948409A (ja) * 1982-09-10 1984-03-19 Teikoku Seiyaku Kk 矯正的歯牙移動促進剤
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
IE59361B1 (en) * 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
SE9501670L (sv) * 1995-05-05 1996-06-10 Perstorp Ab Omläggningsset
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6593369B2 (en) * 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
WO1999066870A1 (en) * 1998-06-25 1999-12-29 Lavipharm Laboratories, Inc. A device and method for the treatment of erectile dysfunction
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
KR100402334B1 (ko) * 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제

Similar Documents

Publication Publication Date Title
JP2006514068A5 (enExample)
EP2387394B1 (en) Transdermal administration of tamsulosin
US12090139B2 (en) Formulations comprising triptan compounds
CA2512015A1 (en) Topical stabilized prostaglandin e compound dosage forms
US20170112780A1 (en) Pharmaceutical composition for application to nail
ES2396598T3 (es) Preparaciones en forma de suspensiones acuosas
EP2116230A3 (en) Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
JP2005512995A5 (enExample)
US20020192243A1 (en) Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
JP2002521468A5 (enExample)
JP2008526854A5 (enExample)
ES2744864T3 (es) Agentes potenciadores de la administración transdérmica y transmucosa de fármacos
WO2008030389A3 (en) Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
JP2008545777A5 (enExample)
NZ547376A (en) Transdermal pharmaceutical spray formulations comprising a VP/VA copolymer and a non-aqueous vehicle
US11337962B2 (en) Formulations comprising triptan compounds
WO2004071499A1 (ja) ジクロフェナク含有貼付剤
RU2003125096A (ru) Психостимулирующее средство
US20020192242A1 (en) Transdermal and topical administration of bone density regulators using basic enhancers
JPS63152316A (ja) 経皮吸収製剤
WO2002069967A1 (en) Percutaneous absorption compositions
TH65242A (th) รูปแบบยาที่ให้ทางปากสำหรับโพรไพวีรีนหรือเกลือที่สามารถยอมรับได้ทางเภสัชกรรมของมันที่มีการปลดปล่อยส่วนประกอบออกฤทธิ์เร็วที่นานขึ้น